170 related articles for article (PubMed ID: 32992358)
1. Preoperative Differentiation of Benign and Malignant Non-epithelial Ovarian Tumors: Clinical Features and Tumor Markers.
Gomes TA; Campos EA; Yoshida A; Sarian LO; Andrade LALA; Derchain SF
Rev Bras Ginecol Obstet; 2020 Sep; 42(9):555-561. PubMed ID: 32992358
[TBL] [Abstract][Full Text] [Related]
2. Ovarian masses in children and adolescents - an analysis of 521 clinical cases.
Zhang M; Jiang W; Li G; Xu C
J Pediatr Adolesc Gynecol; 2014 Jun; 27(3):e73-7. PubMed ID: 24157281
[TBL] [Abstract][Full Text] [Related]
3. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
Ahmed AA; Abdou AM
Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
[TBL] [Abstract][Full Text] [Related]
5. Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses.
Pitta Dda R; Sarian LO; Barreta A; Campos EA; Andrade LL; Fachini AM; Campbell LM; Derchain S
BMC Cancer; 2013 Sep; 13():423. PubMed ID: 24044637
[TBL] [Abstract][Full Text] [Related]
6. Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis.
Shin KH; Kim HH; Kwon BS; Suh DS; Joo JK; Kim KH
Ann Lab Med; 2020 Jan; 40(1):40-47. PubMed ID: 31432638
[TBL] [Abstract][Full Text] [Related]
7. Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer.
Furrer D; Grégoire J; Turcotte S; Plante M; Bachvarov D; Trudel D; Têtu B; Douville P; Bairati I
PLoS One; 2019; 14(6):e0218621. PubMed ID: 31220149
[TBL] [Abstract][Full Text] [Related]
8. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
9. Biomarker-based early detection of epithelial ovarian cancer based on a five-protein signature in patient's plasma - a prospective trial.
Hasenburg A; Eichkorn D; Vosshagen F; Obermayr E; Geroldinger A; Zeillinger R; Bossart M
BMC Cancer; 2021 Sep; 21(1):1037. PubMed ID: 34530759
[TBL] [Abstract][Full Text] [Related]
10. The differential diagnostic value and clinical significance of serum HE4 in ovarian disease with elevated CA125.
Li W; Wang D
Arch Gynecol Obstet; 2020 May; 301(5):1219-1225. PubMed ID: 32266526
[TBL] [Abstract][Full Text] [Related]
11. A retrospective study of reproductive outcomes after fertility-sparing surgery and postoperative adjuvant chemotherapy in malignant ovarian germ cell tumors and sex cord-stromal tumors.
Zhang N; Chen R; Hua K; Zhang Y
J Ovarian Res; 2017 Jul; 10(1):52. PubMed ID: 28750644
[TBL] [Abstract][Full Text] [Related]
12. Different features of the histopathological subtypes of ovarian tumors in pre- and postmenopausal women.
Jung EJ; Eom HM; Byun JM; Kim YN; Lee KB; Sung MS; Kim KT; Jeong DH
Menopause; 2017 Sep; 24(9):1028-1032. PubMed ID: 28832426
[TBL] [Abstract][Full Text] [Related]
13. Laparoscopic management of early-stage malignant nonepithelial ovarian tumors: surgical and survival outcomes.
Shim SH; Kim DY; Lee SW; Park JY; Kim JH; Kim YM; Kim YT; Nam JH
Int J Gynecol Cancer; 2013 Feb; 23(2):249-55. PubMed ID: 23318909
[TBL] [Abstract][Full Text] [Related]
14. CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages.
Wang Z; Tao X; Ying C
Dis Markers; 2019; 2019():6241743. PubMed ID: 31737130
[TBL] [Abstract][Full Text] [Related]
15. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age.
Kondalsamy-Chennakesavan S; Hackethal A; Bowtell D; ; Obermair A
Gynecol Oncol; 2013 Jun; 129(3):467-71. PubMed ID: 23500084
[TBL] [Abstract][Full Text] [Related]
16. [Diagnostic value of CA125, HE4 and Copenhagen Index in differentiating benign from malignant epithelial ovarian tumors].
Gong SP; Chen YN; Zhang YD; Yao W; Chen L; Liu SS; Wu H
Nan Fang Yi Ke Da Xue Xue Bao; 2017 May; 37(5):628-632. PubMed ID: 28539285
[TBL] [Abstract][Full Text] [Related]
17. Predictors of ovarian malignancy in children: overcoming clinical barriers of ovarian preservation.
Papic JC; Finnell SM; Slaven JE; Billmire DF; Rescorla FJ; Leys CM
J Pediatr Surg; 2014 Jan; 49(1):144-7; discussion 147-8. PubMed ID: 24439599
[TBL] [Abstract][Full Text] [Related]
18. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management.
Bandiera E; Romani C; Specchia C; Zanotti L; Galli C; Ruggeri G; Tognon G; Bignotti E; Tassi RA; Odicino F; Caimi L; Sartori E; Santin AD; Pecorelli S; Ravaggi A
Cancer Epidemiol Biomarkers Prev; 2011 Dec; 20(12):2496-506. PubMed ID: 22028406
[TBL] [Abstract][Full Text] [Related]
19. Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors.
Landolfo C; Achten ETL; Ceusters J; Baert T; Froyman W; Heremans R; Vanderstichele A; Thirion G; Van Hoylandt A; Claes S; Oosterlynck J; Van Rompuy AS; Schols D; Billen J; Van Calster B; Bourne T; Van Gorp T; Vergote I; Timmerman D; Coosemans A
Gynecol Oncol; 2020 Dec; 159(3):811-819. PubMed ID: 32994054
[TBL] [Abstract][Full Text] [Related]
20. [Rare ovarian tumors: report of a series of 11 cases of malignant non-epithelial ovarian tumors].
Mamouni N; Saadi H; Erraghay S; Bouchikhi C; Banani A
Pan Afr Med J; 2015; 20():174. PubMed ID: 26113917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
